Skip Ribbon Commands Skip to main content
Share This

Dear Sir/Madam,

Sanofi announced on 15th December, 2015 that it has entered into exclusive negotiations with Boehringer Ingelheim (BI).  The proposed transaction would consist of a strategic exchange of Merial and BI Consumer Healthcare, whereby Merial would become part of Boehringer Ingelheim’s Animal Health division.
The execution of definitive agreements is expected for the second half of 2016 following consultations with the relevant regulatory and social bodies.  Until the approval and closing of the proposed transaction, Merial and Boehringer Ingelheim remain competitors and will continue to act as independent companies.
Please be assured that Merial is dedicated to keep providing you with a comprehensive range of products to enhance the health and wellbeing of a wide range of animals.  Merial will continue its focus and investment in product innovation and services to meet your evolving needs.
Your interests remain of the utmost importance to us and we continue to remain fully committed to your needs and concerns.
If you have any specific questions, your dedicated Merial representative is available to address them.  As part of our commitment, we will keep you updated on the important steps throughout the process.
On behalf of Merial I would like to take this opportunity to thank you for your ongoing support and to wish you a Merry Christmas and a prosperous New Year.
Yours faithfully,
Bernhard Fuerst
Managing Director